Imagine trying to paint a tiny target on a moving object without being able to see where the paint actually lands. This technology acts like a high-tech camera that lets doctors see exactly where radiation hits a tumor in real-time. It ensures the medicine hits the cancer and stays away from healthy organs, making the treatment safer and more effective.
Proton therapy lacks real-time dose verification, leading to uncertainties in dose delivery. This prevents truly personalized treatment and risks exposing healthy tissues to radiation.
A proof-of-concept for real-time dose verification using organic scintillators and AI-enhanced image reconstruction.
If you are a radiotherapy equipment manufacturer dealing with the lack of real-time feedback in proton therapy — this project developed a proof-of-concept for dose verification that allows for adaptive, personalized treatment. This enables the creation of smarter, safer proton therapy machines.
If you are an AI medical imaging developer dealing with slow image reconstruction during radiation — this project developed AI-accelerated models for simultaneous detection of radiation species. This allows for faster, more accurate tissue compositional analysis during treatment.
If you are a proton therapy center dealing with uncertainties in dose delivery to radioresistant tumors — this project developed a non-invasive measurement system using organic scintillators. This helps in reducing toxicity and improving patient quality-of-life post-treatment.
Based on available project data, specific pricing is not mentioned, but the project utilizes inexpensive organic scintillator technology to keep costs low.
No, the project aims to reach Technology Readiness Level 4, which is a proof-of-concept tested under pre-clinical conditions.
Based on available project data, there are no specific details provided regarding patents or licensing agreements.
The project explicitly considers integration into the proton therapy clinical workflow to enable dose-guided real-time adaptive therapy.
The project period runs from 2024-03-01 to 2028-02-29.
The consortium is heavily research-oriented, consisting of 9 partners across 4 countries. It is dominated by universities (5) and research organizations (3), with only 1 SME and a low industry ratio of 11%. This suggests the project is in an early discovery phase, though it covers the full value chain from technology providers to PT clinics.
Hogskulen pa Vestlandet
Contact us to track the TRL 4 validation of this proton therapy technology.
